On 22 August 2026 the Ministry of Health and Family Welfare notified a restriction on the manufacture, sale and distribution of all fixed dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride, requiring every such product to carry the warning "Fixed Dose Combination shall not be used in children below four years of age" on its label, package insert and promotional literature. The notification was issued under Section 26A of the Drugs and Cosmetics Act, 1940, in the interest of public health, and takes effect from the date of its publication in the Official Gazette.
Two words in that sentence do most of the work: all and restriction. An earlier notification, S.O. 1717(E) of 15 April 2025, had imposed the same warning on certain FDCs containing these two ingredients. The 2026 notification closes the gap by extending the requirement to every formulation containing both. And this is a restriction, not a prohibition — the medicines remain on the market, relabelled. Understanding why the government chose that rung of the ladder, and what legal machinery it had to move through to get there, is the substance of this story.
What a fixed dose combination is, and when it becomes "irrational"
A fixed dose combination is two or more active pharmaceutical ingredients combined in a fixed ratio inside a single dosage form — one tablet, one syrup, one drop.
FDCs are not inherently bad. Some of the most important therapies in global public health are FDCs, and for good reason. Antiretroviral therapy for HIV, the four-drug combination for tuberculosis, and artemisinin-based combination therapy for malaria all exist as fixed combinations because combining them does something a loose collection of pills cannot: it makes non-adherence to part of the regimen impossible. A patient cannot quietly drop one anti-TB drug and keep taking the other three, which is precisely how drug resistance is manufactured. Combination also reduces pill burden, simplifies procurement and cuts packaging cost.
The problem is the other category. An FDC is called irrational when the combination has no therapeutic justification — when the ingredients treat unrelated conditions, when their pharmacokinetics do not match so one drug is still active long after the other has cleared, when the combination exposes patients to a drug they do not need, or when the fixed ratio makes it impossible to titrate one component without changing the other. That last point is the decisive one in paediatrics. A child's dose is weight-based. If a syrup locks an antihistamine and a decongestant into a fixed ratio, a prescriber who wants less of one is forced to give less of both.
Irrational FDCs also create a diagnostic problem. When a patient reacts badly to a four-ingredient syrup, attributing the adverse event to a specific molecule becomes guesswork, which corrupts the pharmacovigilance data the regulator depends on.
India has an unusually large irrational-FDC problem for a structural reason worth remembering: for decades, state drug licensing authorities issued manufacturing licences for combinations that had never been approved as new drugs by the central regulator, on the argument that the individual ingredients were already approved. The result was thousands of combinations circulating without any central assessment of the combination itself. Almost every FDC controversy in India traces back to that federal loophole.
The two molecules in question
Chlorpheniramine maleate is a first-generation H1 antihistamine. First-generation means it crosses the blood-brain barrier readily, which is why it sedates. In small children the central effects are unpredictable — sedation in some, paradoxical agitation in others — and the drug also carries anticholinergic activity that can produce dry mouth, urinary retention, and at higher exposures, confusion and cardiac effects. The margin between a therapeutic and a toxic dose narrows sharply as body weight falls.
Phenylephrine hydrochloride is an alpha-1 adrenergic agonist used as an oral decongestant. Its problem is different and, in a way, more damning. Oral phenylephrine undergoes extensive first-pass metabolism, so very little of a swallowed dose reaches the nasal vasculature. In September 2023 the United States FDA's Nonprescription Drugs Advisory Committee voted 16-0 that the available scientific data do not support the effectiveness of 10 mg oral phenylephrine as a nasal decongestant. In November 2024 the FDA issued a proposed order to remove oral phenylephrine from the over-the-counter monograph for cold, cough and allergy products, with the public comment period closing on 7 May 2025.
Be precise about what that FDA finding does and does not say. The committee's concern was efficacy, not safety at the recommended dose; the FDA explicitly clarified it was not raising safety issues about oral phenylephrine at recommended doses in adults. But stack the two findings together and the risk-benefit arithmetic for a toddler becomes hard to defend: one ingredient whose benefit by the oral route is seriously contested, combined with another whose central and anticholinergic risks are real and rise as body weight falls. That is why the restriction bites at the youngest end and not across the board.
Why four years specifically? The line is not arbitrary. In October 2008, following FDA scrutiny, member companies of the US Consumer Healthcare Products Association voluntarily relabelled oral paediatric cough and cold medicines to read "do not use" in children under four, up from the earlier under-two threshold. India's own regulator arrived at the same line: a Subject Expert Committee took up the question on 6 June 2023, and on 18 December 2023 the Drugs Controller General of India wrote to state and union territory drug controllers directing manufacturers of the chlorpheniramine 2 mg + phenylephrine 5 mg drops formulation to carry the under-four warning. The 2025 and 2026 notifications converted that administrative direction into statutory form.
The legal architecture behind the notification
India's drug law rests on the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. Within that framework, four bodies matter for the CDS general studies paper.
Section 26A is the operative power here. It allows the Central Government, where it is satisfied that the use of a drug is likely to involve any risk to human beings or animals, or that a drug lacks the therapeutic value claimed, or contains ingredients for which there is no therapeutic justification, to regulate, restrict or prohibit its manufacture, sale or distribution by notification, if it is necessary or expedient in the public interest. Note the three-rung ladder built into the section — regulate, restrict, prohibit. The August 2026 notification uses the middle rung.
CDSCO, the Central Drugs Standard Control Organisation, functions under the Directorate General of Health Services in the Ministry of Health and Family Welfare and is India's national regulatory authority for drugs. It operates through six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories.
The DCGI, the Drugs Controller General (India), heads CDSCO. The DCGI approves new drugs and clinical trials and sets standards, while licensing for the manufacture of most other drugs sits with state drug controllers — the federal split that keeps recurring in every enforcement failure.
DTAB, the Drugs Technical Advisory Board, is the highest statutory technical body advising the central and state governments on technical matters under the Act. It is chaired by the Director General of Health Services. Alongside it sits the Drugs Consultative Committee, chaired by the DCGI, whose mandate is to secure uniformity across India in the administration of the Act. Aspirants preparing the general science section of the CDS syllabus should be able to name the chair of each body, because that is the single most examinable distinction between them.
Why the notification names its committees — the 2016-2018 precedent
The press note is careful to say the decision followed the recommendations of an Expert Committee and the DTAB. That carefulness has a history.
On 10 March 2016 the government prohibited 344 fixed dose combinations by notification. On 1 December 2016, the Delhi High Court, in a judgment by Justice Rajiv Sahai Endlaw, quashed those notifications, holding that they had been issued without following the statutorily prescribed procedure and without consultation with the DTAB and the Drugs Consultative Committee. Roughly 6,000 affected products came back to the market.
The government appealed. On 15 December 2017 the Supreme Court held that Section 26A does not mandate prior consultation with the DTAB — the Centre's power is genuine and independent — but it nonetheless referred the bulk of the FDCs to the DTAB or a committee appointed by it for examination. The DTAB sub-committee that followed recommended prohibition of 343 FDCs and regulatory restrictions on six. On 14 September 2018 the government prohibited 328 FDCs, exempting 15 that had been approved before 1988. In August 2024 a further 156 FDCs were prohibited on the same statutory basis.
The lesson the ministry drew is visible in the drafting of the 2026 notification. The Supreme Court gave the Centre a wide substantive power but the Delhi High Court had already shown that the procedural record is where a notification dies. Naming the Expert Committee and DTAB in the press note is not decoration; it is litigation-proofing.
The timing, and the distinction that matters most
It would be naive to read this notification without the 2025 cough syrup crisis behind it. In early October 2025, children in Chhindwara district of Madhya Pradesh began dying of acute kidney injury after taking Coldrif syrup manufactured by Sresan Pharmaceuticals. Testing found the syrup contained 48.6% diethylene glycol, an industrial solvent. Madhya Pradesh banned the product on 2 October 2025, and by mid-October the toll had reached about 24 children, mostly under five. The World Health Organization issued an alert covering Coldrif and two other Indian-made syrups, Respifresh TR and ReLife. India had been here before: in 2022, syrups from Maiden Pharmaceuticals were linked to around 66 to 70 child deaths in The Gambia, and Marion Biotech's products to 19 deaths in Uzbekistan, with WHO counting more than 300 deaths across affected countries.
Now hold two ideas apart, because conflating them is the single most common error in answers on this topic. Diethylene glycol contamination is a manufacturing quality failure — a solvent substitution, caught or missed by testing of raw materials and finished product. It is a Good Manufacturing Practice and inspection problem. The chlorpheniramine-phenylephrine restriction is a rational-use failure — the molecules are exactly what the label says they are, and the question is whether that combination should be given to a two-year-old at all.
The same bottle of paediatric syrup can fail in both ways, which is why the crisis created the political space for the second kind of reform. But they call for different remedies: contamination is answered by risk-based inspection, mandatory testing of every glycerin and propylene glycol consignment, and traceability; irrationality is answered by Section 26A notifications and prescriber education. A CDS answer that treats the FDC restriction as a response to the DEG deaths misreads the mechanism, and this distinction is exactly the kind of nuance that separates a good general science and public policy answer from a merely factual one.
What changes on the ground, and the honest objection
Practically, manufacturers must revise labels, inserts and promotional material. Enforcement falls to state drug inspectors, and the deterrent is the Act's penalty structure for misbranded and spurious drugs.
The obvious objection is that a warning on a bottle is a weak instrument. Cough and cold syrups in India are frequently bought without a prescription, dispensed on a chemist's advice, and given by a parent reading a label in a second language. A statutory warning changes what the manufacturer must print; it does not by itself change what a chemist recommends on a Tuesday evening. The counter-view, which the ministry effectively adopted, is that an outright prohibition on a widely used class would face immediate industrial litigation and would remove a product that is not dangerous to older children, whereas a mandatory, uniform, age-specific warning is defensible, quick and hard to challenge. Regulation by labelling is a compromise. Whether it is the right one depends entirely on enforcement follow-through — which is the honest two-sided line to carry into an essay.
🔑 Revision block
The notification. 22 August 2026 · Ministry of Health and Family Welfare · restricts all FDCs containing chlorpheniramine maleate + phenylephrine hydrochloride · mandatory warning "shall not be used in children below four years of age" on label, package insert and promotional literature · effective from Gazette publication.
The legal basis. Section 26A, Drugs and Cosmetics Act, 1940 — Centre may regulate → restrict → prohibit where a drug involves risk, lacks claimed therapeutic value, or contains ingredients without therapeutic justification, and action is necessary in the public interest. This notification uses the middle rung, not a ban.
Who advised whom. Expert Committee + DTAB (highest statutory technical body, chaired by the Director General of Health Services) → Central Government. DCC is chaired by the DCGI and handles centre-state uniformity. CDSCO sits under DGHS in the Ministry of Health and Family Welfare and is headed by the DCGI.
The precedent chain. 10 March 2016: 344 FDCs prohibited → 1 December 2016: Delhi High Court quashes for lack of DTAB/DCC consultation → 15 December 2017: Supreme Court holds prior DTAB consultation is not mandatory but refers FDCs to a DTAB sub-committee → 14 September 2018: 328 FDCs prohibited, 15 pre-1988 FDCs exempted → August 2024: 156 more prohibited.
Dates and figures to carry. S.O. 1717(E) of 15 April 2025 covered certain FDCs · DCGI letter of 18 December 2023 followed a Subject Expert Committee recommendation of 6 June 2023 · the drops formulation is chlorpheniramine 2 mg + phenylephrine 5 mg · US FDA advisory committee voted 16-0 in September 2023 against oral phenylephrine's efficacy · Coldrif contained 48.6% diethylene glycol.
The trap. Do not merge the two failure modes. Diethylene glycol deaths are a manufacturing quality failure answered by inspection and raw-material testing. The FDC restriction is a rational-use failure answered by Section 26A. And note that the FDA's phenylephrine finding was about efficacy, not toxicity.
The two-sided line, for essay and interview. A statutory age warning is fast, uniform and litigation-resistant — but it regulates the printer, not the pharmacy counter, in a market where paediatric cough syrup is routinely bought without a prescription. The measure is only as strong as state-level enforcement and prescriber behaviour.
🎯 Practice MCQs
1. The August 2026 restriction on fixed dose combinations of chlorpheniramine maleate and phenylephrine hydrochloride was issued under which provision?
(a) Section 5 of the Drugs and Cosmetics Act, 1940 (b) Section 26A of the Drugs and Cosmetics Act, 1940 (c) Section 3 of the Essential Commodities Act, 1955 (d) Rule 122E of the Drugs Rules, 1945
→ (b) Section 26A empowers the Central Government to regulate, restrict or prohibit a drug in the public interest; it is the standard basis for FDC actions.
2. The Drugs Technical Advisory Board is chaired by the:
(a) Drugs Controller General (India) (b) Union Health Secretary (c) Director General of Health Services (d) Secretary, Department of Pharmaceuticals
→ (c) DTAB meetings are chaired by the Director General of Health Services; the Drugs Consultative Committee is the body chaired by the DCGI.
3. Which of the following best describes an "irrational" fixed dose combination?
(a) Any combination of more than one active ingredient (b) A combination whose ingredients lack therapeutic justification or cannot be independently titrated (c) Any combination not manufactured under a central licence (d) A combination sold without a prescription
→ (b) Rational FDCs such as anti-TB and antiretroviral combinations are widely used; irrationality turns on absence of therapeutic justification, mismatched pharmacokinetics and loss of dose flexibility.
4. In December 2016, the Delhi High Court quashed the Centre's notification banning 344 FDCs principally on the ground that:
(a) The Centre had no power to ban drugs under the 1940 Act (b) The statutory consultation procedure had not been followed (c) The drugs had been proved safe in clinical trials (d) Drug regulation is exclusively a State subject
→ (b) The Court held the notifications were issued without following the prescribed procedure, including consultation with the DTAB and the Drugs Consultative Committee.
5. The Central Drugs Standard Control Organisation functions under which body?
(a) The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers (b) The Indian Council of Medical Research (c) The Directorate General of Health Services, Ministry of Health and Family Welfare (d) The National Pharmaceutical Pricing Authority
→ (c) CDSCO is India's national drug regulatory authority and works under the DGHS in the Ministry of Health and Family Welfare; it is headed by the DCGI.
📋 How this gets asked (PYQ pattern)
Drug regulation reaches CDS and NDA papers through three well-worn doors, and this notification opens all three at once.
The first is the statute-and-body identification question. Papers regularly ask which Act governs drug regulation in India, which ministry a regulator reports to, or which body performs a named function. CDSCO, the DCGI, DTAB and the National Pharmaceutical Pricing Authority form a natural confusion set, and the examiner exploits it — placing NPPA (which is under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, and handles price control) as a distractor for CDSCO (under the Ministry of Health and Family Welfare, and handles safety and quality). Learn each body by ministry, chair and function, not by name alone.
The second is the section-number question. Section 26A has become an examinable number in its own right because it is invoked every time a drug is banned, and each ban generates a news cycle. Statement-based questions on it typically pair a correct claim about the Centre's power with an incorrect claim that prior DTAB consultation is legally mandatory — a distinction the Supreme Court settled in December 2017 and which therefore makes an excellent trap.
The third is the science-behind-the-news door, and it is the one candidates neglect. Papers ask what an antihistamine does, what class a decongestant belongs to, or why combination therapy is used in tuberculosis. Those are general science questions with a current affairs shell, and they reward the candidate who read past the headline into the pharmacology. Building the habit of reading a health notification for its mechanism rather than only its date is what the general science preparation track is meant to develop.
The fresh hook this cycle is the extension from certain FDCs in April 2025 to all formulations in August 2026, and the fact that the restriction sits between the 2025 Coldrif contamination deaths and the 2016-2018 FDC litigation. For an interview or an essay, the strongest available line is the one distinguishing a quality-control failure from a rational-use failure — the same product category failing in two entirely different ways, requiring two entirely different remedies.
The daily CDS and OTA current affairs digests on this site work through each day's notifications and press releases the way this one has been worked through — background verified, mechanism explained, practice questions attached — so you are not left choosing between reading everything and reading nothing. If you want that discipline built into a structured timetable, our upcoming CDS and OTA batches in Delhi run written preparation and SSB training together.